ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

SPRY ARS Pharmaceuticals Inc

8.41
-0.25 (-2.89%)
18 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
ARS Pharmaceuticals Inc SPRY NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.25 -2.89% 8.41 10:00:00
Open Price Low Price High Price Close Price Previous Close
8.57 8.35 8.64 8.41 8.66
more quote information »

Recent News

Date Time Source Heading
18/6/202410:47EDGAR2Form SC 13D/A - General statement of acquisition of..
14/6/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202409:18EDGAR2Form SC 13D/A - General statement of acquisition of..
17/5/202409:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202421:01EDGAR2Form 8-K - Current report
10/5/202408:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202406:08EDGAR2Form 8-K - Current report
10/5/202406:05GLOBEARS Pharmaceuticals Highlights neffy Regulatory Progress and..
30/4/202423:01GLOBEARS Pharmaceuticals Submits Response for neffy® (epinephrine..
04/4/202400:01GLOBEARS Pharmaceuticals Submits Response to FDA Complete..
22/3/202407:05GLOBEARS Pharmaceuticals Provides Business Update and Reports..
08/3/202408:05GLOBEARS Pharmaceuticals Reviews Recent Clinical Updates and..
08/3/202404:56EDGAR2Form 8-K - Current report
07/3/202401:01GLOBEARS Pharmaceuticals to Participate in the Leerink Partners..
02/3/202412:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202413:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202404:08EDGAR2Form 144 - Report of proposed sale of securities
27/2/202401:01GLOBEARS Pharmaceuticals announces neffy® meets primary endpoints..
23/2/202401:01GLOBEARS Pharmaceuticals to Host Virtual neffy® Investor Day on..
21/2/202401:01GLOBEARS Pharma Announces Favorable Topline Results from Repeat..
06/2/202401:01GLOBEARS Pharmaceuticals to Present Positive Clinical Efficacy..
05/1/202408:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202408:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202408:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202408:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/11/202308:02EDGAR2Form 8-K - Current report
10/11/202308:00GLOBEARS Pharmaceuticals Reports Third Quarter 2023 Financial..
10/11/202303:02GLOBEARS Pharmaceuticals Announces Presentation of Clinical Data..
07/10/202300:57DJNARS Pharmaceuticals to Meet With FDA on Neffy Rejection
07/10/202300:03GLOBEARS Pharmaceuticals Announces Scheduling of a Type A Meeting..
04/10/202300:03GLOBESingle and Repeat Dose Clinical Study of neffy (epinephrine..
26/9/202306:17EDGAR2Form 8-K - Current report
21/9/202300:20DJNARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy..
20/9/202320:30DJNARS Pharmaceuticals Shares Sink Premarket as FDA Rejects..
20/9/202320:05EDGAR2Form 8-K - Current report
20/9/202312:49GLOBEFDA Issues Complete Response Letter for neffy® (epinephrine..
02/9/202306:15EDGAR2Form SC 13D/A - General statement of acquisition of..
11/8/202306:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202306:05EDGAR2Form 8-K - Current report
11/8/202306:00GLOBEARS Reports Second Quarter 2023 Financial Results and..
29/6/202311:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202311:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202306:32EDGAR2Form 8-K - Current report
20/6/202322:00GLOBEARS Pharmaceuticals Announces PDUFA Date Extension for..

Your Recent History

Delayed Upgrade Clock